{"id":"NCT03004248","sponsor":"Revance Therapeutics, Inc.","briefTitle":"Safety of Single and Repeat Treatments of DaxibotulinumtoxinA for Injection for Treatment of Moderate to Severe Glabellar Lines","officialTitle":"An Open-Label, Multi-Center Trial to Assess the Safety of Single and Repeat Treatments of DaxibotulinumtoxinA for Injection for Treatment of Moderate to Severe Glabellar Lines (SAKURA OPEN-LABEL SAFETY)","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2016-12-09","primaryCompletion":"2018-10-17","completion":"2018-10-17","firstPosted":"2016-12-28","resultsPosted":"2022-07-13","lastUpdate":"2022-07-13"},"enrollment":2691,"design":{"allocation":"NA","model":"SINGLE_GROUP","masking":"NONE","primaryPurpose":"TREATMENT"},"conditions":["Glabellar Frown Lines"],"interventions":[{"type":"BIOLOGICAL","name":"Botulinum Toxins, Type A","otherNames":["DaxibotulinumtoxinA"]}],"arms":[{"label":"DaxibotulinumtoxinA 40 units","type":"EXPERIMENTAL"}],"summary":"This is a long term safety study of DaxibotulinumtoxinA for Injection for the treatment of moderate to severe glabellar lines following single and repeat administration.","primaryOutcome":{"measure":"Incidence of Treatment Emergent Adverse Events (TEAE)","timeFrame":"0-36 weeks","effectByArm":[{"arm":"Treatment Cycle 1","deltaMin":831,"sd":null},{"arm":"Treatment Cycle 2","deltaMin":267,"sd":null},{"arm":"Treatment Cycle 3","deltaMin":118,"sd":null}],"pValues":[]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":4,"exclusionCount":5},"locations":{"siteCount":61,"countries":["United States","Canada"]},"refs":{"pmids":["32773447","32773446"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":29,"n":2691},"commonTop":["Headache"]}}